激肽釋放酶原(PK)真核蛋白
Eukaryotic Prekallikrein (PK)
KLKB1; KLK3; Fletcher Factor; Kallikrein B,Plasma; Kininogenin; Plasma prekallikrein
- 編號(hào)EPB801Ra61
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱(chēng)，不同的物種。
- 來(lái)源真核表達(dá)
- 宿主293F cell
- 內(nèi)毒素水平<1.0EU/µg(LAL法測(cè)定)
- 亞細(xì)胞定位分泌
- 預(yù)測(cè)分子量70.7kDa
- 實(shí)際分子量75kDa(差異分析請(qǐng)參閱說(shuō)明書(shū))
- 片段與標(biāo)簽Gly20~Ala638 with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 5% Trehalose.
- 性狀凍干粉
- 純度> 95%
- 等電點(diǎn)8.1
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請(qǐng)參見(jiàn)活性蛋白。 - 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 1056 ¥ 2640 ¥ 5280 ¥ 15840 ¥ 39600
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Figure. SDS-PAGE
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月，-80°C不超過(guò)12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| EPB801Ra61 | 激肽釋放酶原(PK)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Int J Immunopathol Pharmacol | Altered activities of kininase II, an angiotensin converting enzyme, prekallikrein, and nitric oxide in Kuwaiti patients with type 2 diabetes [PubMed: 25964383] |
| Thromb Res | Factor XII–mediated contact activation related to poor prognosis in disseminated intravascular coagulation [PubMed: 26706311] |
| Thrombosis Research | Factor XII-mediated contact activation related to poor prognosis in disseminated intravascular coaCavia (Guinea pig )lation [Pubmed:26706311] |
| Annals of Laboratory Medicine | The First Case of Congenital Prekallikrein Deficiency in Korea With a Novel Pathogenic Variant (c. 1198G> T) [Pubmed: 30430790] |
| J Cell Mol Med | Huaier shows anti?\cancer activities by inhibition of cell growth, migration and energy metabolism in lung cancer through PI3K/AKT/HIF?\1|á pathway [33377619] |
| J Thromb Thrombolysis | Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors [Pubmed:34993714] |
留言咨詢
